Si l'histoire de C-17 et C-18 a été assez détaillée dans le manga, Akira Toriyama avait révélé dans un tome spécial en 2014 ...

Une roche formée dans les profondeurs de Mars Dans le détail, ce « rocher rayé noir et blanc comme aucun autre observé sur ...

Le marbre est une roche métamorphique dérivée du calcaire, existant dans une grande diversité de coloris, pouvant présenter des veines, ou marbrures (veines et coloris sont dus à des inclusions ...

Roche doesn’t think so. “I think we don’t see anything that should be slowing Vabysmo momentum down,” Teresa Graham, CEO of Roche Pharmaceuticals, said during a press conference Wednesday ...

Roche’s new TAGS technology overcomes the technical limitations of a typical 4-plex test result in previous solutions, using a novel, proprietary approach. Without having to upgrade hardware or ...

Un schiste est une roche qui a pour particularité d'avoir un aspect feuilleté, et de se débiter en plaques fines ou « feuillet rocheux ». On dit qu'elle présente une schistosité. Il peut s'agir d'une ...

Roche has reported early-stage clinical data with an oral GLP-1 agonist acquired as part of its $3.1 billion takeover of Carmot Therapeutics as it tries to catch up with the leaders in the fast ...

Roche has returned the rights to UCB’s anti-tau antibody bepranemab, walking away from a $120 million bet on the Alzheimer’s disease drug candidate on the cusp of the release of phase 2a data.

Roche ROG-1.53%decrease; red down pointing triangle confirmed its profit outlook for the year after its eye drug Vabysmo, multiple-sclerosis treatment Ocrevus and hemophilia injection Hemlibra ...

After forming a gene therapy partnership with Dyno Therapeutics in 2020, Roche is back for more. In a new deal potentially worth more than $1 billion, Roche is paying Dyno $50 million upfront to ...

Roche is reported to be considering the sale of its cancer data specialist Flatiron Health, just a few years after it bought the company for $1.9 billion. The Financial Times first revealed the ...

Roche CEO: not good to limit competition in this space Roche says not itself, but others affected by Catalent deal Swiss drugmaker joins US peer Lilly in voicing opposition Eli Lilly and advocacy ...